Premium
Effects of Polymer 3D Architecture, Size, and Chemistry on Biological Transport and Drug Delivery In Vitro and in Orthotopic Triple Negative Breast Cancer Models
Author(s) -
Pearce Amanda K.,
AnaneAdjei Akosua B.,
Cavanagh Robert J.,
Monteiro Patricia F.,
Bennett Thomas M.,
Taresco Vincenzo,
Clarke Phil A.,
Ritchie Alison A.,
Alexander Morgan R.,
Grabowska Anna M.,
Alexander Cameron
Publication year - 2020
Publication title -
advanced healthcare materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.288
H-Index - 90
eISSN - 2192-2659
pISSN - 2192-2640
DOI - 10.1002/adhm.202000892
Subject(s) - in vivo , biodistribution , doxorubicin , drug delivery , nanotechnology , methacrylamide , materials science , drug carrier , chemistry , in vitro , biomedical engineering , biophysics , polymer , biochemistry , organic chemistry , copolymer , biology , medicine , chemotherapy , surgery , acrylamide , microbiology and biotechnology
The size, shape, and underlying chemistries of drug delivery particles are key parameters which govern their ultimate performance in vivo. Responsive particles are desirable for triggered drug delivery, achievable through architecture change and biodegradation to control in vivo fate. Here, polymeric materials are synthesized with linear, hyperbranched, star, and micellar‐like architectures based on 2‐hydroxypropyl methacrylamide (HPMA), and the effects of 3D architecture and redox‐responsive biodegradation on biological transport are investigated. Variations in “stealth” behavior between the materials are quantified in vitro and in vivo, whereby reduction‐responsive hyperbranched polymers most successfully avoid accumulation within the liver, and none of the materials target the spleen or lungs. Functionalization of selected architectures with doxorubicin (DOX) demonstrates enhanced efficacy over the free drug in 2D and 3D in vitro models, and enhanced efficacy in vivo in a highly aggressive orthotopic breast cancer model when dosed over schedules accounting for the biodistribution of the carriers. These data show it is possible to direct materials of the same chemistries into different cellular and physiological regions via modulation of their 3D architectures, and thus the work overall provides valuable new insight into how nanoparticle architecture and programmed degradation can be tailored to elicit specific biological responses for drug delivery.